New CAR T Cell for Multiple Myeloma Approved by FDA New CAR T Cell for Multiple Myeloma Approved by FDA
Ciltacabtagene autoleucel (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves New CAR T Cell for Multiple Myeloma FDA Approves New CAR T Cell for Multiple Myeloma
Ciltacabtagene autoleucel (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) has approved Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
Review provides a consensus statement from a global panel. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 3, 2022 Category: Consumer Health News Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Use of fall risk-increasing drugs in older adults with multiple myeloma: a cross-sectional study - Machado TRL, Menezes de P ádua CA, Drummond PLM, Silveira LP, Malta JS, Santos RMMD, Costa NL, Reis AMM.
OBJECTIVE: To investigate the use of fall risk-increasing drugs (FRIDs) and associated factors and to assess the use of medicines that induce neuropathy in older adults with multiple myeloma (MM). METHODS: Cross-sectional study with older adults wi... (Source: SafetyLit)
Source: SafetyLit - January 31, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS
...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
This Calgary couple is working to destigmatize cancer for Black Canadians
When Yinka Oladele’s husband was diagnosed with multiple myeloma in 2016, she automatically became his caregiver. But she struggled to find the information and resources she needed to navigate his diagnosis as a Black patient. (Source: CBC | Health)
Source: CBC | Health - January 24, 2022 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news
Lab Notes: Penn Medicine's $14M NIH grant; NRx seeks designation for drug candidate
Philadelphia-area life sciences news this week includes updates on research on how to use CAR T-cell therapy to help kidney transplant patients, breakthrough therapy designation request for a drug candidate, and a drug for relapsed or refractory multiple myeloma patients. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 30, 2021 Category: Pharmaceuticals Authors: John George Source Type: news
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of treatments ...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news
CAR-T Cell Therapy for Multiple Myeloma May Lead to Parkinson-Like Symptoms CAR-T Cell Therapy for Multiple Myeloma May Lead to Parkinson-Like Symptoms
Researchers at Mount Sinai in New York have reported a previously unknown neurological side effect in a patient with multiple myeloma who received CAR-T cell therapy in a clinical trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
COVID Vaccines Offer Only Some Protection for People With Myeloma
New research shows COVID-19 vaccines provide far less protection to people with multiple myeloma than to survivors of other types of cancer. (Source: WebMD Health)
Source: WebMD Health - December 15, 2021 Category: Consumer Health News Source Type: news
COVID Vaccines Offer Only Some Protection for People Battling Myeloma
WEDNESDAY, Dec. 15, 2021 -- COVID-19 vaccination provides far less protection to people with multiple myeloma than to survivors of other types of cancer, new research shows.
The findings highlight the need for multiple myeloma patients“to be... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 15, 2021 Category: General Medicine Source Type: news
COVID Vaccines Offer Only Some Protection for People Battling Myeloma
Title: COVID Vaccines Offer Only Some Protection for People Battling MyelomaCategory: Health NewsCreated: 12/15/2021 12:00:00 AMLast Editorial Review: 12/15/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 15, 2021 Category: Cancer & Oncology Source Type: news
